Current therapy for CKD includes angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, which act by decreasing proteinuria, lowering blood pressure, and thus retarding CKD progression (Levey and Coresh, 2012; Ruggenenti et al., 2012). This evidence concerns the gene ACE and chronic kidney disease.